Abstract: Obiective To investigate the efficacy of ultrasound interventional therapy for patients with compensated liver cirrhosis due to hepatitis B infection. Methods 181 patients with compensated liver cirrhosis were enrolled in this study，including 109 cases in the treatment group，and 72 cases in the control group. The patients in the control group were given nucleoside analogues，and in the treatment group were given interventional ultrasound treatment at the base of antiviral therapy. All patients were followed-up by ultrasound-guided liver biopsy for histological activity index and hepatic fibrosis index，and liver function，blood routine and abdominal ultrasound check-up after 1 years，2 years，and 3 years of treatment. Result There was no significant difference of serum HBV DNA loss rates between the two groups；The serum albumin level in patients of treatment group at the end of 3 years was（40.9±4.1） g/L，significantly higher than in the control group[（38.7±3.4） g/L，P＜0.05]，prothrombin time activity were（69.7±11.4） %，significantly higher than that in the control group [（65.9±9.4） %，P＜0.05]. The diameter of portal vein and splenic length were （1.18±0.14） cm and（11.74±1.18） cm，significantly lower than those in the control group [（1.24±0.14） cm and （12.78±1.43） cm，P＜0.05]. The histopathological improvement rate in treatment group was 54.1%，significantly higher than 25.0% in the control group（P＜0.01）. The HAI and HFI were （3.64±0.86） and （3.87±0.84），were both significantly lower than in the control group [（8.94±1.42） and （6.83±1.12），respectively，P＜0.05]. Conclusion The treatment in our series can effectively improve the liver function of patients with compensated liver cirrhosis，reducing portal hypertension and improving liver fibrosis.

Key words: Liver cirrhosis, Hepatitis B, Interventional ultrasound treatment, Liver pathology